Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04338269
Registration number
NCT04338269
Ethics application status
Date submitted
6/04/2020
Date registered
8/04/2020
Titles & IDs
Public title
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Query!
Scientific title
A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Query!
Secondary ID [1]
0
0
WO41994
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CONTACT-03
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Cabozantinib
Experimental: Atezo+Cabo - Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
Active comparator: Cabozantinib - Participants will receive cabozantinib every day.
Treatment: Drugs: Atezolizumab
Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
Treatment: Drugs: Cabozantinib
Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1
Query!
Assessment method [1]
0
0
Progression Free Survival (PFS) is defined as the time from randomization to disease progression, as determined by the Independent Review Facility (IRF) per RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who have not experienced disease progression or death were censored at the last tumor assessment date. Data for patients with no postbaseline tumor assessments were censored at the randomization date.
Query!
Timepoint [1]
0
0
From randomization to the first occurrence of disease progression according to RECIST v1.1 (up to 2 years 5 months).
Query!
Primary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
From randomization to death due to any cause. Data for patients who are not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Patients who do not have post-baseline information were censored at the date of randomization.
Query!
Timepoint [2]
0
0
From randomization to death due to any cause (up to 2 years 5 months).
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS) as Assessed by Investigators (INV-PFS), According to RECIST v1.1
Query!
Assessment method [1]
0
0
Progression Free Survival (PFS) is defined as the time from randomization to disease progression, as determined by the Investigators per RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who have not experienced disease progression or death were censored at the last tumor assessment date. Data for patients with no postbaseline tumor assessments were censored at the randomization date.
Query!
Timepoint [1]
0
0
From randomization to the first occurrence of disease progression according to RECIST v1.1 or death from any cause (whichever occurs first) (up to 2 years 5 months).
Query!
Secondary outcome [2]
0
0
Investigator-assessed Overall Response Rate (ORR) (INV-ORR) According to RECIST v1.1
Query!
Assessment method [2]
0
0
Overall Response Rate (ORR) is defined as the proportion of participants who had an objective response (complete response \[CR\] or partial response \[PR\]) on two consecutive occasions at least 4 weeks apart according to RECIST v1.1. in the ORR evaluable population, defined as patients with measurable disease at baseline.
Query!
Timepoint [2]
0
0
From randomization to the first occurrence of disease progression according to RECIST v1.1 or death from any cause (whichever occurs first) (up to 2 years 5 months).
Query!
Secondary outcome [3]
0
0
Independent Review Facility (IRF)-Assessed Overall Response Rate (ORR) (IRF-ORR) According to RECIST v1.1
Query!
Assessment method [3]
0
0
Overall Response Rate (ORR) is defined as the proportion of participants who had an objective response (complete response \[CR\] or partial response \[PR\]) on two consecutive occasions at least 4 weeks apart according to RECIST v1.1. in the ORR evaluable population, defined as patients with measurable disease at baseline.
Query!
Timepoint [3]
0
0
From randomization to the first occurrence of disease progression according to RECIST v1.1 or death from any cause (whichever occurs first) (up to 2 years 5 months).
Query!
Secondary outcome [4]
0
0
Investigator-assessed Duration of Response (DOR) (INV-DOR) According to RECIST v1.1
Query!
Assessment method [4]
0
0
Duration of Response (DOR) is defined as the time from the first occurrence of a confirmed objective response (complete response \[CR\] or partial response \[PR\]) to disease progression, or death, whichever occurs first. Data for participants who have not experienced disease progression or death will be censored at the last tumor assessment date. If no tumor assessments were performed after the date of the first occurrence of CR or PR, data for DOR will be censored at the date of the first occurrence of CR or PR.
Query!
Timepoint [4]
0
0
From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 2 years 5 months)
Query!
Secondary outcome [5]
0
0
Independent Review Facility (IRF)-Assessed Duration of Response (DOR) (IRF-DOR) According to RECIST v1.1
Query!
Assessment method [5]
0
0
Duration of Response (DOR) is defined as the time from the first occurrence of a confirmed objective response (complete response \[CR\] or partial response \[PR\]) to disease progression, or death, whichever occurs first. Data for participants who have not experienced disease progression or death will be censored at the last tumor assessment date. If no tumor assessments were performed after the date of the first occurrence of CR or PR, data for DOR will be censored at the date of the first occurrence of CR or PR.
Query!
Timepoint [5]
0
0
From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 2 years 5 months)
Query!
Eligibility
Key inclusion criteria
* Histologically confirmed locally advanced or metastatic clear cell or non-clear cell (papillary, chromophobe, and unclassified only) RCC. RCC with sarcomatoid features is allowed. Patients with the chromophobe subtype of non-clear cell RCC must have sarcomatoid differentiation.
* Radiographic disease progression to prior ICI therapy for RCC. Patients who experienced radiographic tumor progression during or within 6 months after the last dose of adjuvant ICI are also eligible. ICI is defined by anti-PD-L1 or anti-PD1 antibody including atezolizumab, avelumab, pembrolizumab, durvalumab, or nivolumab. Only patients for whom the immediate preceding line of therapy was an ICI are allowed.
* Measurable disease per RECIST v1.1
* Evaluable IMDC risk score
* Archival tumor specimen, and pretreatment tumor tissue from fresh biopsy at screening, if clinically feasible. Both archival and fresh samples are preferred.
* KPS score of >=70
* Recovery to baseline or Grade </= 1 NCI CTCAE v5.0 from toxicities related to any prior treatments, unless adverse events are clinically nonsignificant and/or stable in the opinion of the investigator. Grade 2 alopecia is allowed for study participation
* Adequate hematologic and end-organ function
* Negative HIV test at screening
* Negative hepatitis B testing at screening
* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Treatment with anti-cancer therapy within 14 days prior to initiation of study treatment
* Patients received cabozantinib at any time prior to screening
* Patients who received more than one ICI treatment in the locally advanced or metastatic setting
* Patients who received more than two prior lines of therapy in the locally advanced or metastatic setting
* Patients who have received a mammalian target of rapamycin (mTOR) inhibitor in any setting
* Symptomatic, untreated, or actively progressing CNS metastases
* History of leptomeningeal disease
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
* Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
* History of malignancy other than renal carcinoma within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
* Radiotherapy for RCC within 14 days prior to Day 1 of Cycle 1
* Active tuberculosis
* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after final dose of atezolizumab and 4 months after final dose of cabozantinib
* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety
* Pharmacologically uncompensated, symptomatic hypothyroidism
* Uncontrolled hypertension defined as sustained blood pressure >150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment (all countries except France); sustained BP > 140 mmHg systolic or > 90 mmHg diastolic despite optimal antihypertensive treatment (France only)
* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, unstable arrhythmia, or unstable angina) within 3 months prior to initiation of study treatment
* Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1
* History of congenital QT syndrome
* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion
* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitor dabigatran, direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g. clopidogrel)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/11/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
522
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Macquarie University Hospital - Macquarie Park
Query!
Recruitment hospital [2]
0
0
Orange Hospital - Orange
Query!
Recruitment hospital [3]
0
0
Icon Cancer Foundation - South Brisbane
Query!
Recruitment hospital [4]
0
0
Bendigo Cancer Centre - Bendigo
Query!
Recruitment postcode(s) [1]
0
0
2113 - Macquarie Park
Query!
Recruitment postcode(s) [2]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
3550 - Bendigo
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nevada
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Buenos Aires
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Ciudad Autonoma Bs As
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Herlev
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Besançon Cedex
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Bordeaux
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Caen
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Clermont Ferrand
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lille
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Lyon
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Nice
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Nimes
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Paris
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Strasbourg
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Villejuif
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Chemnitz
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Frankfurt
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Freiburg
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Halle (Saale)
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Hamburg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Hannover
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Muenster
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
München
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Tübingen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Ulm
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Athens
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
Chaidari
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Larissa
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Thessaloniki
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Campania
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Emilia-Romagna
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Lazio
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Lombardia
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Marche
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Piemonte
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Puglia
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Umbria
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Veneto
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Hokkaido
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Ibaraki
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Kanagawa
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Okayama
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Osaka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Tokushima
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tokyo
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Daejeon
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Gyeonggi-do
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Gyeongsangnam-do
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Jeollanam-do
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Seongnam-si
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Seoul
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
?ód?
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Brzozów
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Bydgoszcz
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Bytom
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Otwock
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Pozna?
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Warszawa
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Wroc?aw
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Jaroslavl
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Leningrad
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Moskovskaja Oblast
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Sankt Petersburg
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Novosibirsk
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Asturias
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Cantabria
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Cordoba
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Islas Baleares
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Pontevedra
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Burgos
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Caceres
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Lugo
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Madrid
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Malaga
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Murcia
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Navarra
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Sevilla
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Valencia
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Blackburn
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Leicester
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
London
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Manchester
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Exelixis
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Chugai
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04338269
Query!
Trial related presentations / publications
Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/69/NCT04338269/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/69/NCT04338269/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04338269